171 related articles for article (PubMed ID: 27565399)
41. Dystroglycan: from biosynthesis to pathogenesis of human disease.
Barresi R; Campbell KP
J Cell Sci; 2006 Jan; 119(Pt 2):199-207. PubMed ID: 16410545
[TBL] [Abstract][Full Text] [Related]
42. Human natural killer-1 sulfotransferase (HNK-1ST)-induced sulfate transfer regulates laminin-binding glycans on α-dystroglycan.
Nakagawa N; Manya H; Toda T; Endo T; Oka S
J Biol Chem; 2012 Aug; 287(36):30823-32. PubMed ID: 22801424
[TBL] [Abstract][Full Text] [Related]
43. Mutagenesis at the alpha-beta interface impairs the cleavage of the dystroglycan precursor.
Sciandra F; Bozzi M; Morlacchi S; Galtieri A; Giardina B; Brancaccio A
FEBS J; 2009 Sep; 276(17):4933-45. PubMed ID: 19694806
[TBL] [Abstract][Full Text] [Related]
44. Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations.
Huizing M; Rakocevic G; Sparks SE; Mamali I; Shatunov A; Goldfarb L; Krasnewich D; Gahl WA; Dalakas MC
Mol Genet Metab; 2004 Mar; 81(3):196-202. PubMed ID: 14972325
[TBL] [Abstract][Full Text] [Related]
45. Insights from molecular dynamics simulations: structural basis for the V567D mutation-induced instability of zebrafish alpha-dystroglycan and comparison with the murine model.
Pirolli D; Sciandra F; Bozzi M; Giardina B; Brancaccio A; De Rosa MC
PLoS One; 2014; 9(7):e103866. PubMed ID: 25078606
[TBL] [Abstract][Full Text] [Related]
46. Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma.
Miller MR; Ma D; Schappet J; Breheny P; Mott SL; Bannick N; Askeland E; Brown J; Henry MD
Mol Cancer; 2015 Jul; 14():141. PubMed ID: 26220087
[TBL] [Abstract][Full Text] [Related]
47. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
Toda T
Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
[TBL] [Abstract][Full Text] [Related]
48. Investigating the functions of LARGE: lessons from mutant mice.
Hewitt JE
Methods Enzymol; 2010; 479():367-86. PubMed ID: 20816177
[TBL] [Abstract][Full Text] [Related]
49. A putative Src homology 3 domain binding motif but not the C-terminal dystrophin WW domain binding motif is required for dystroglycan function in cellular polarity in Drosophila.
Yatsenko AS; Gray EE; Shcherbata HR; Patterson LB; Sood VD; Kucherenko MM; Baker D; Ruohola-Baker H
J Biol Chem; 2007 May; 282(20):15159-69. PubMed ID: 17355978
[TBL] [Abstract][Full Text] [Related]
50. Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase.
Bao X; Kobayashi M; Hatakeyama S; Angata K; Gullberg D; Nakayama J; Fukuda MN; Fukuda M
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12109-14. PubMed ID: 19587235
[TBL] [Abstract][Full Text] [Related]
51. The conserved WW-domain binding sites in Dystroglycan C-terminus are essential but partially redundant for Dystroglycan function.
Yatsenko AS; Kucherenko MM; Pantoja M; Fischer KA; Madeoy J; Deng WM; Schneider M; Baumgartner S; Akey J; Shcherbata HR; Ruohola-Baker H
BMC Dev Biol; 2009 Feb; 9():18. PubMed ID: 19250553
[TBL] [Abstract][Full Text] [Related]
52. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies.
Barresi R; Michele DE; Kanagawa M; Harper HA; Dovico SA; Satz JS; Moore SA; Zhang W; Schachter H; Dumanski JP; Cohn RD; Nishino I; Campbell KP
Nat Med; 2004 Jul; 10(7):696-703. PubMed ID: 15184894
[TBL] [Abstract][Full Text] [Related]
53. SEA domain proteolysis determines the functional composition of dystroglycan.
Akhavan A; Crivelli SN; Singh M; Lingappa VR; Muschler JL
FASEB J; 2008 Feb; 22(2):612-21. PubMed ID: 17905726
[TBL] [Abstract][Full Text] [Related]
54. The effect of the pathological V72I, D109N and T190M missense mutations on the molecular structure of α-dystroglycan.
Covaceuszach S; Bozzi M; Bigotti MG; Sciandra F; Konarev PV; Brancaccio A; Cassetta A
PLoS One; 2017; 12(10):e0186110. PubMed ID: 29036200
[TBL] [Abstract][Full Text] [Related]
55. Molecular recognition by LARGE is essential for expression of functional dystroglycan.
Kanagawa M; Saito F; Kunz S; Yoshida-Moriguchi T; Barresi R; Kobayashi YM; Muschler J; Dumanski JP; Michele DE; Oldstone MB; Campbell KP
Cell; 2004 Jun; 117(7):953-64. PubMed ID: 15210115
[TBL] [Abstract][Full Text] [Related]
56. Alpha-dystroglycan, the usual suspect?
Brancaccio A
Neuromuscul Disord; 2005 Dec; 15(12):825-8. PubMed ID: 16289897
[TBL] [Abstract][Full Text] [Related]
57. α-dystroglycan is a potential target of matrix metalloproteinase MMP-2.
Sbardella D; Sciandra F; Gioia M; Marini S; Gori A; Giardina B; Tarantino U; Coletta M; Brancaccio A; Bozzi M
Matrix Biol; 2015 Jan; 41():2-7. PubMed ID: 25483986
[TBL] [Abstract][Full Text] [Related]
58. The many roles of dystroglycan in nervous system development and function: Dystroglycan and neural circuit development: Dystroglycan and neural circuit development.
Jahncke JN; Wright KM
Dev Dyn; 2023 Jan; 252(1):61-80. PubMed ID: 35770940
[TBL] [Abstract][Full Text] [Related]
59. Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.
Martin PT; Shelton GD; Dickinson PJ; Sturges BK; Xu R; LeCouteur RA; Guo LT; Grahn RA; Lo HP; North KN; Malik R; Engvall E; Lyons LA
Neuromuscul Disord; 2008 Dec; 18(12):942-52. PubMed ID: 18990577
[TBL] [Abstract][Full Text] [Related]
60. Limb girdle muscular dystrophy type 2I: No correlation between clinical severity, histopathology and glycosylated α-dystroglycan levels in patients homozygous for common FKRP mutation.
Alhamidi M; Brox V; Stensland E; Liset M; Lindal S; Nilssen Ø
Neuromuscul Disord; 2017 Jul; 27(7):619-626. PubMed ID: 28479227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
